Advances in immunosuppression for renal transplantation

Area of Science:

• Immunology
• Transplantation Medicine
• Pharmacology

Background:

• Improving outcomes after organ transplantation, including acute and chronic antibody-mediated rejection, requires immunosuppressants with fewer adverse and nephrotoxic effects.
• Expanded donor criteria and transplantation in immunized patients highlight the need for novel therapeutic strategies.
• Recent drug development has faced challenges, yet promising new compounds are emerging.

Purpose of the Study:

• To review novel immunosuppressive compounds developed to improve organ transplant outcomes.
• To discuss agents targeting T cell depletion and activation pathways.
• To examine therapies aimed at preventing antibody-mediated rejection.

Main Methods:

• Literature review of recent advancements in immunosuppressant drug development for organ transplantation.
• Analysis of compounds designed to modulate T cell responses (depletion and activation).
• Evaluation of therapeutic strategies targeting antibody-mediated rejection.

Main Results:

• Several promising new compounds are under development to prevent acute and chronic transplant rejection.
• Identified agents focus on removing or inhibiting allogenic T cells.
• Discussed are compounds that interfere with antibody-mediated rejection pathways.

Conclusions:

• Development of novel immunosuppressants is essential for advancing organ transplantation.
• Emerging therapies show promise in mitigating T cell-mediated and antibody-mediated rejection.
• These advancements are critical for managing complex transplant scenarios, including expanded criteria donors and immunized recipients.